Citi Raises Arcturus Therapeutics Price Target to $49, Keeps Buy Rating
ByAinvest
Tuesday, Aug 12, 2025 11:25 pm ET1min read
ARCT--
Citigroup analyst Yigal Nochomovitz maintained a "Buy" rating for Arcturus Therapeutics (ARCT) and raised the price target for the stock to $49.00 from the previous target of $47.00. This adjustment reflects a 4.26% increase in the price target, announced on August 12, 2025 [1].
The recent upgrade comes as Arcturus Therapeutics reported better-than-expected Q2 financial results, driving a 27.9% increase in stock price to $14.56 [2]. The company's pipeline includes promising therapeutic candidates such as LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19, which are focused on rare diseases like cystic fibrosis and respiratory conditions.
Analysts are particularly optimistic about the upcoming ARCT-032 Phase 2 readout in September, which Citigroup believes offers a favorable risk/reward profile. The company is also advancing enrollment for adult CF participants in its Phase 2 multiple ascending dose CF study and expects to complete enrollment as planned by year-end [3].
Arcturus Therapeutics' financial results for the second quarter ended June 30, 2025, showed revenues of $28.3 million and $57.7 million for the three and six months, respectively, representing decreases compared to the same periods in 2024. Operating expenses were $39.9 million for the three months and $86.1 million for the six months, reflecting a decrease driven by lower manufacturing costs and reduced clinical trial expenses [3].
Based on the one-year price targets offered by 10 analysts, the average target price for Arcturus Therapeutics is $61.80, with a high estimate of $140.00 and a low estimate of $25.00. The average target implies an upside of 442.58% from the current price of $11.39 [1].
The consensus recommendation from 11 brokerage firms is currently 1.5, indicating a "Buy" status. GuruFocus estimates the GF Value for Arcturus Therapeutics in one year to be $15.84, suggesting an upside of 39.07% from the current price of $11.39 [1].
References:
[1] https://www.gurufocus.com/news/3055345/citigroup-raises-price-target-for-arcturus-therapeutics-arct-to-49-arct-stock-news
[2] https://www.inkl.com/news/mercury-systems-posts-better-than-expected-earnings-joins-green-dot-arcturus-therapeutics-and-other-big-stocks-moving-higher-on-tuesday
[3] https://finance.yahoo.com/news/arcturus-therapeutics-announces-second-quarter-200100265.html
C--
GDOT--
Citi raised the price target for Arcturus Therapeutics (ARCT) to $49 from $47 and maintained a Buy rating. The firm believes the upcoming ARCT-032 Phase 2 readout in September offers a favorable risk/reward.
Title: Citigroup Raises Price Target for Arcturus Therapeutics (ARCT)Citigroup analyst Yigal Nochomovitz maintained a "Buy" rating for Arcturus Therapeutics (ARCT) and raised the price target for the stock to $49.00 from the previous target of $47.00. This adjustment reflects a 4.26% increase in the price target, announced on August 12, 2025 [1].
The recent upgrade comes as Arcturus Therapeutics reported better-than-expected Q2 financial results, driving a 27.9% increase in stock price to $14.56 [2]. The company's pipeline includes promising therapeutic candidates such as LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19, which are focused on rare diseases like cystic fibrosis and respiratory conditions.
Analysts are particularly optimistic about the upcoming ARCT-032 Phase 2 readout in September, which Citigroup believes offers a favorable risk/reward profile. The company is also advancing enrollment for adult CF participants in its Phase 2 multiple ascending dose CF study and expects to complete enrollment as planned by year-end [3].
Arcturus Therapeutics' financial results for the second quarter ended June 30, 2025, showed revenues of $28.3 million and $57.7 million for the three and six months, respectively, representing decreases compared to the same periods in 2024. Operating expenses were $39.9 million for the three months and $86.1 million for the six months, reflecting a decrease driven by lower manufacturing costs and reduced clinical trial expenses [3].
Based on the one-year price targets offered by 10 analysts, the average target price for Arcturus Therapeutics is $61.80, with a high estimate of $140.00 and a low estimate of $25.00. The average target implies an upside of 442.58% from the current price of $11.39 [1].
The consensus recommendation from 11 brokerage firms is currently 1.5, indicating a "Buy" status. GuruFocus estimates the GF Value for Arcturus Therapeutics in one year to be $15.84, suggesting an upside of 39.07% from the current price of $11.39 [1].
References:
[1] https://www.gurufocus.com/news/3055345/citigroup-raises-price-target-for-arcturus-therapeutics-arct-to-49-arct-stock-news
[2] https://www.inkl.com/news/mercury-systems-posts-better-than-expected-earnings-joins-green-dot-arcturus-therapeutics-and-other-big-stocks-moving-higher-on-tuesday
[3] https://finance.yahoo.com/news/arcturus-therapeutics-announces-second-quarter-200100265.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet